Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants
Markus Harboe Olsen,Mathias Lühr Hansen,Theis Lange,Christian Gluud,Lehana Thabane,Gorm Greisen,Janus Christian Jakobsen,SafeBoosC-III Trial Group,Adelina Pellicer,Afif El-Kuffash,Agata Bargiel,Ana Alarcon,Andrew Hopper,Anita Truttmann,Anja Hergenhan,Anja Klamer,Anna Curley,Anne Marie,Anne Smits,Asli Cinar Memisoglu,Barbara Krolak-Olejnik,Beata Rzepecka,Begona Loureiro Gonzales,Beril Yasa,Berndt Urlesberger,Catalina Morales-Betancourt,Chantal Lecart,Claudia Knöepfli,Cornelia Hagmann,David Healy,Ebru Ergenekon,Eleftheria Hatzidaki,Elena Bergon-Sendin,Eleni Skylogianni,Elzbieta Rafinska-Wazny,Emmanuele Mastretta,Eugene Dempsey,Eva Valverde,Evangelina Papathoma,Fabio Mosca,Gabriel Dimitriou,Gerhard Pichler,Giovanni Vento,Gitte Holst Hahn,Gunnar Naulaers,Guoqiang Cheng,Hans Fuchs,Hilal Ozkan,Isabel De Las Cuevas,Itziar Serrano-Vinuales,Iwona Sadowska-Krawczenko,Jachym Kucera,Jakub Tkaczyk,Jan Miletin,Jan Sirc,Jana Baumgartner,Jonathan Mintzer,Julie De Buyst,Karen McCall,Konstantina Tsoni,Kosmas Sarafidis,Lars Bender,Laura Serrano Lopez,Le Wang,Liesbeth Thewissen,Lin Huijia,Lina Chalak,Ling Yang,Luc Cornette,Luis Arruza,Maria Wilinska,Mariana Baserga,Marie Isabel Skov Rasmussen,Marta Mencia Ybarra,Marta Teresa Palacio,Martin Stocker,Massimo Agosti,Merih Cetinkaya,Miguel Alsina,Monica Fumagalli,Munaf M Kadri,Mustafa Senol Akin,Münevver Baş,Nilgun Koksal,Olalla Otero Vaccarello,Olivier Baud,Pamela Zafra,Peter Agergaard,Peter Korcek,Pierre Maton,Rebeca Sanchez-Salmador,Ruth Del Rio Florentino,Ryszard Lauterbach,Salvador Piris Borregas,Saudamini Nesargi,Serife Suna,Shashidhar Appaji Rao,Shujuan Zeng,Silvia Pisoni,Simon Hyttel-Sørensen,Sinem Gulcan Kersin,Siv Fredly,Suna Oguz,Sylwia Marciniak,Tanja Karen,Tomasz Szczapa,Tone Nordvik,Veronika Karadyova,Xiaoyan Gao,Xin Xu,Zachary Vesoulis,Zhang Peng,Zhaoqing Yin
DOI: https://doi.org/10.1186/s13063-023-07720-3
IF: 2.728
2023-11-16
Trials
Abstract:Background: Extremely preterm infants have a high mortality and morbidity. Here, we present a statistical analysis plan for secondary Bayesian analyses of the pragmatic, sufficiently powered multinational, trial-SafeBoosC III-evaluating the benefits and harms of cerebral oximetry monitoring plus a treatment guideline versus usual care for such infants. Methods: The SafeBoosC-III trial is an investigator-initiated, open-label, randomised, multinational, pragmatic, phase III clinical trial with a parallel-group design. The trial randomised 1601 infants, and the frequentist analyses were published in April 2023. The primary outcome is a dichotomous composite outcome of death or severe brain injury. The exploratory outcomes are major neonatal morbidities associated with neurodevelopmental impairment later in life: (1) bronchopulmonary dysplasia; (2) retinopathy of prematurity; (3) late-onset sepsis; (4) necrotising enterocolitis; and (5) number of major neonatal morbidities (count of bronchopulmonary dysplasia, retinopathy of prematurity, and severe brain injury). The primary Bayesian analyses will use non-informed priors including all plausible effects. The models will use a Hamiltonian Monte Carlo sampler with 1 chain, a sampling of 10,000, and at least 25,000 iterations for the burn-in period. In Bayesian statistics, such analyses are referred to as 'posteriors' and will be presented as point estimates with 95% credibility intervals (CrIs), encompassing the most probable results based on the data, model, and priors selected. The results will be presented as probability of any benefit or any harm, Bayes factor, and the probability of clinical important benefit or harm. Two statisticians will analyse the blinded data independently following this protocol. Discussion: This statistical analysis plan presents a secondary Bayesian analysis of the SafeBoosC-III trial. The analysis and the final manuscript will be carried out and written after we publicise the primary frequentist trial report. Thus, we can interpret the findings from both the frequentists and Bayesian perspective. This approach should provide a better foundation for interpreting of our findings. Trial registration: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.